EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh

Marjahan Akhtar iD, Md Rashedul Islam iD, Zahid Hasan Khan, Afroza Akter, Imam Tauheed iD, Tasnuva Ahmed iD, Ishtiakul Islam Khan iD, Mohammad Ashraful Amin, Fatema Khaton, Farhana Khanam, Md Taufiqul Islam, Prasanta Kumar Biswas und 12 weitere

Vaccines · 15.06.2026 · 14 (6) · 531

DOI: 10.3390/vaccines14060531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 15.06.2026. Verfasst von Marjahan Akhtar und 23 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka 1212, Bangladesh. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, United States Agency for International Development, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The dynamics of humoral immune responses following primary and booster COVID-19 vaccinations are crucial to understand in order to optimize vaccination strategies. This study evaluates the magnitude and durability of SARS-CoV-2-specific IgG antibody responses across different vaccines in a large cohort of Bangladeshi adults.

Methods

A total of 6300 adults from nine hospitals across eight divisions of Bangladesh were enrolled. Participants received two primary doses of either ChAdOx1 nCoV-19 (Covishield, Serum Institute of India, n = 2855), mRNA-1273 (Moderna, n = 578), BNT162b2 (Pfizer-BioNTech, n = 121), or Vero-cell-inactivated (Sinopharm, n = 2746) vaccines. Booster doses were administered at one-year intervals post-primary vaccination. SARS-CoV-2 spike receptor-binding domain (RBD)-specific IgG antibody responses were measured by ELISA using serum from vaccinees at multiple time points after two primary and two booster doses.

Results

A total of 3745 individuals received booster 1 (third dose), with 59% receiving heterologous boosters (a different vaccine regimen than the primary doses). Only 5.5% (n = 347) of participants received a second booster one year after the first booster (among them, 99% received BNT162b2). Our results suggest that heterologous boosters with the mRNA vaccine induced higher IgG levels than homologous boosters for individuals who received primary vaccination with adenovirus vector-based ChAdOx1 nCoV-19 or a Vero-cell-inactivated vaccine. However, in those who initially received the mRNA-based vaccine, both homologous and heterologous boosters produced comparable IgG responses. Among all vaccine types, booster immunization with the Vero-cell-inactivated vaccine induced the lowest antibody responses. Longitudinal analysis demonstrated significantly high IgG levels over the 12 months following the first booster (p < 0.0001); however, IgG levels declined significantly after the second booster dose (fourth dose).

Conclusions

Heterologous boosting strategies, particularly those involving mRNA vaccines, elicit stronger and more sustained IgG responses compared to a homologous booster. However, antibody waning after the second booster highlights the need for continued monitoring and potential additional vaccine strategies.

Schlagwörter

Stichwörter der Autor:innen

COVID-19IgG kineticsantibody responsebooster doseheterologous boostingvaccination

Autor:innen und Institutionen

  • Infectious Diseases Division, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka 1212, Bangladesh.
  • Bangladesh Institute of Tropical & Infectious Diseases (BITID), Chittagong 4316, Bangladesh.
  • Institute of Epidemiology, Disease Control and Research (IEDCR), Dhaka 1212, Bangladesh.
  • Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02214, USA.
  • Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.
  • Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.

ORCID-Profile: Marjahan Akhtar, Md Rashedul Islam, Imam Tauheed, Tasnuva Ahmed, Ishtiakul Islam Khan, Ahmed Nawsher Alam, Sayera Banu, Tahmina Shirin, Taufiqur Rahman Bhuiyan

Förderung

  • Gates Foundation
  • United States Agency for International Development
  • Bill and Melinda Gates Foundation
  • Global Emerging Leader Award
  • National Institutes of Health
  • icddr,b

Zitieren

APA

Akhtar, M., Islam, M. R., Khan, Z. H., Akter, A., Tauheed, I., Ahmed, T., Khan, I. I., Amin, M. A., Khaton, F., Khanam, F., Islam, M. T., Biswas, P. K., Rashid, R., Rashid, M. M., Hossain, M. Z., Alam, A. N., Alamgir, A. S. M., Ryan, E. T., Banu, S., …, & Qadri, F. (2026). Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh. Vaccines, 14(6), 531. https://doi.org/10.3390/vaccines14060531

Vancouver

Akhtar M, Islam MR, Khan ZH, Akter A, Tauheed I, Ahmed T, et al. Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh. Vaccines. 2026;14(6):531. doi:10.3390/vaccines14060531

BibTeX
@article{Akhtar2026,
  author = {Akhtar, Marjahan and Islam, Md Rashedul and Khan, Zahid Hasan and Akter, Afroza and Tauheed, Imam and Ahmed, Tasnuva and Khan, Ishtiakul Islam and Amin, Mohammad Ashraful and Khaton, Fatema and Khanam, Farhana and Islam, Md Taufiqul and Biswas, Prasanta Kumar and Rashid, Rumana and Rashid, Md Mamunur and Hossain, Md Zakir and Alam, Ahmed Nawsher and Alamgir, A S M and Ryan, Edward T and Banu, Sayera and Shirin, Tahmina and Chowdhury, Fahima and Khan, Ashraful Islam and Bhuiyan, Taufiqur Rahman and Qadri, Firdausi},
  title = {Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {531},
  doi = {10.3390/vaccines14060531}
}
Kostenlos starten →